English
You are here: Home » Products » Oncology Hot Spots Standard » IHC

IHC Reference Standard

Background



Immunohistochemistry (IHC) is a technique that uses the principle of specific antibodies binding to target antigens, combined with histological techniques, to locate and detect specific proteins or peptide molecules in tissues or cells. Through staining or fluorescent labeling, immunohistochemistry can visually display the distribution of target molecules in tissues or cells under a microscope.


IHC Applications





Currently, immunohistochemistry detection technology is mainly used in the following fields:


Pathological diagnosis: such as tumor marker (HER2, PD-L1, ER/PR, etc.) detection.


Scientific research experiments: protein expression and distribution research, signal pathway research.


Drug development: target validation, drug action mechanism research.


Forensic medicine: identification of specific proteins in tissue samples.




IHC Clinical significance




Precise disease diagnosis


Immunohistochemistry can help pathologists accurately classify and diagnose diseases by detecting the expression of specific proteins in tissue samples. For example, specific markers (such as TTF-1, CK7, and CK20) can be used to determine the primary site of the tumor.


Tumor molecular classification


Immunohistochemistry is a core tool for tumor molecular classification. For example, the expression status of ER (estrogen receptor), PR (progesterone receptor), and HER2 is an important basis for breast cancer classification, which directly affects the selection of endocrine therapy and targeted therapy.


Therapeutic target detection


Immunohistochemistry can detect the expression of specific targets in tumor cells, providing a basis for targeted therapy and immunotherapy. For example, PD-L1 expression level is an important indicator for evaluating the efficacy of immune checkpoint inhibitors (such as pembrolizumab).


Guiding clinical trial enrollment


Immunohistochemistry test results are an important criterion for screening patients for enrollment in many clinical trials. For example, PD-L1 expression level is one of the enrollment conditions for immunotherapy clinical trials.              





CB-Gene IHC quality control products: 

compliant, accurate and efficient



✅ Ready-to-use design:ready to use, no need for slicing or labeling, saving 50% of quality control preparation time;

 Ultra-long stability: stored at -20℃ for 3 years, strict quality control for batch consistency;

Full process adaptation: compatible with mainstream automation platforms such as Leica, Roche, Dako, and supports multiple color development systems such as DAB and fluorescence.



Application Scenarios






Antibody/reagent verification:

Before the first use of new antibodies, verify the sensitivity and cross-reaction to avoid "invalid experiments";


Daily quality control:

Synchronously stain the quality control slides for each batch of experiments to monitor the instrument and operation stability in real time;


Inter-laboratory comparison:

The same quality control slides are distributed to multiple laboratories to quickly locate "problem links" (such as repair conditions, antibody failure);


Staff training:

Standardized quality control slides are used as "reference answers" to help novices quickly master the interpretation standards.





CB-Gene

Relying on its own huge cell resource library, powerful and reliable cell expression screening technology, and stable FFPE cell wax block preparation process, CB-Gene has completed several IHC quality control products that can cover multiple targets such as CLDN18.2, EGFR, HER2, ALK, NTRK, etc., and is constantly developing more cutting-edge biological targets.



Quick Links

Product Category

Lentivirus Integration Standard
Copyright © 2025 Nanjing CB-Gene Biotechnology Co., Ltd. Sitemap. Privacy Policy